Spark Therapeutics
3737 Market Street
Suite 1300
Philadelphia
Pennsylvania
10104
United States
Tel: 888-772-7560
Website: http://www.sparktx.com/
Email: info@sparktx.com
About Spark Therapeutics
Spark Therapeutics is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first approved treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies.
Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark’s founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines.
Spark is based in Philadelphia, PA and was spun out of The Children's Hospital of Philadelphia in October 2013. In May 2014, Spark announced the completion of a $72.8 million Series B financing led by Sofinnova Ventures, bringing the company's total funding raised to $82.8 million to-date. To learn more about Spark visit www.sparktx.com.
YEAR FOUNDED:
2013
LEADERSHIP:
Founders: Jeffrey Marrazzo, J. Fraser Wright and Katherine High
CEO: Jeffrey Marrazzo
CTO: J. Fraser Wright
CSO (Scientific): Katherine High
JOBS:
Please click here for Spark Therapeutics job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW SPARKS THERAPEUTICS:
Tweets by Sparks Therapeutics
166 articles about Spark Therapeutics
-
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
-
National Pharmaceutical Council Welcomes Four Biopharmaceutical Companies as Members
3/6/2018
The National Pharmaceutical Council, a health policy research organization based in Washington, DC, today welcomed four biopharmaceutical companies to its growing membership roster.
-
Here is a look at the life science companies viewed as the most innovative in the world.
-
Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights
2/13/2018
The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 9596288.
-
Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
1/4/2018
Mr. Perez has been the founder and managing partner of Vineyard Sound Advisors since 2015.
-
The therapy is the first type approved by the FDA that targets a disease caused by mutations in a specific gene.
-
Spark Therapeutics Announces First-of-Their-Kind Programs to Improve Patient Access to LUXTURNA (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment
1/3/2018
The company also has reached an agreement in principle with affiliates of Express Scripts to enable the innovative contracting model.
-
Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S.
12/19/2017
The FDA broke new ground today with a first-of-its-kind therapy for eye disease. -
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
-
Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase I/II Dose-Escalation Clinical Trial in Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting and Exposition
12/11/2017
Preliminary data as of Dec. 6, 2017, show a 100-percent reduction in annualized bleeding rate (ABR) and 98-percent reduction in annualized infusion rate (AIR) in first four participants.
-
Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition
12/11/2017
-
Spark Therapeutics is having a really good week in what has been a very good year.
-
Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.
-
Three-Year Follow-Up Phase III Data Provide Additional Information on Efficacy, Durability and Safety Of Investigational LUXTURNA (Voretigene Neparvovec) in Patients With Biallelic RPE65-Mediated Inherited Retinal Disease
11/13/2017
Data show mean improvement demonstrated at one year post one-time administration maintained through at least three years for original intervention cohort, and two years for crossover cohort, with observation ongoing.
-
Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress
11/7/2017
In the three months ended Sept. 30, 2017 and 2016, we recognized $1.9 million and $1.3 million, respectively, of revenue associated with our Pfizer collaboration.
-
Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B
11/7/2017
Spark Therapeutics to receive up to an additional $25 million per terms of amendment.
-
Spark Therapeutics to Host Conference Call on Tuesday, Nov. 7 at 8:30 a.m. ET to Discuss Third Quarter 2017 Results
10/31/2017
The company will host a conference call on Tuesday, Nov. 7, 2017, at 8:30 a.m. ET.
-
Big pharmas are having a good year so far in terms of FDA approvals.
-
A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.
-
On Oct. 13, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark's Luxturna in a vote of 16 to 0.